Howell SB - Search Results

1

APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells.

Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG. Local A, et al. Among authors: howell sb. Mol Cancer Ther. 2018 Jun;17(6):1177-1186. doi: 10.1158/1535-7163.MCT-17-1209. Epub 2018 Apr 6. Mol Cancer Ther. 2018. PMID: 29626127

2

Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo.

Gately DP, Jones JA, Christen R, Barton RM, Los G, Howell SB. Gately DP, et al. Among authors: howell sb. Br J Cancer. 1994 Dec;70(6):1102-6. doi: 10.1038/bjc.1994.455. Br J Cancer. 1994. PMID: 7981060 Free PMC article.

3

Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153.

Gately DP, Sharma A, Christen RD, Howell SB. Gately DP, et al. Among authors: howell sb. Br J Cancer. 1996 Jan;73(1):18-23. doi: 10.1038/bjc.1996.4. Br J Cancer. 1996. PMID: 8554977 Free PMC article.

4

Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.

Nehmé A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JY, Howell SB, Christen RD. Nehmé A, et al. Among authors: howell sb. Cancer Res. 1997 Aug 1;57(15):3253-7. Cancer Res. 1997. PMID: 9242457

5

Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.

Los G, Benbatoul K, Gately DP, Barton R, Christen R, Robbins KT, Vicario D, Kirmani S, Orloff LA, Weisman R, Howell SB. Los G, et al. Among authors: howell sb. Clin Cancer Res. 1999 Jul;5(7):1610-8. Clin Cancer Res. 1999. PMID: 10430059

6

Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel.

de las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, D'Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G. de las Alas MM, et al. Among authors: howell sb. Cancer Chemother Pharmacol. 2000;45(5):381-8. doi: 10.1007/s002800051006. Cancer Chemother Pharmacol. 2000. PMID: 10803921

7

Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.

Okuda T, Lin X, Trang J, Howell SB. Okuda T, et al. Among authors: howell sb. Mol Pharmacol. 2005 Jun;67(6):1852-60. doi: 10.1124/mol.104.010579. Epub 2005 Mar 9. Mol Pharmacol. 2005. PMID: 15758147

8

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.

Lin X, Howell SB. Lin X, et al. Among authors: howell sb. Mol Cancer Ther. 2006 May;5(5):1239-47. doi: 10.1158/1535-7163.MCT-05-0491. Mol Cancer Ther. 2006. PMID: 16731756

9

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.

Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB. Yuan X, et al. Among authors: howell sb. Mol Cancer Ther. 2009 Jul;8(7):1906-15. doi: 10.1158/1535-7163.MCT-09-0106. Epub 2009 Jun 30. Mol Cancer Ther. 2009. PMID: 19567823

10

Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.

Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB. Blair BG, et al. Among authors: howell sb. Mol Pharmacol. 2010 Jun;77(6):912-21. doi: 10.1124/mol.109.062836. Epub 2010 Mar 1. Mol Pharmacol. 2010. PMID: 20194531 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters